JNJ vs MRK
Johnson & Johnson and Merck & Co., both Healthcare
Johnson & Johnson is the larger company at $635B against $358B. On trailing earnings JNJ is the cheaper of the two at a P/E of 40.0 against 115.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year MRK returned +77% against +40% for JNJ. The RyuScore puts MRK ahead, 76 against 68 out of 100.
| Figure | JNJ | MRK |
|---|---|---|
| Last close | $264 | $145 |
| Market cap | $635B | $358B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 40.0 | 115.3 |
| Dividend yield | 2.0% | 2.2% |
| 1-year return | +40% | +77% |
| 5-year return | +88% | +111% |
| RyuScoresector-relative, 1–10 | 68/100 | 76/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Johnson & Johnson
Revenue of $25B in Q3 2026, net income $210M. Its largest reported line is DARZALEX, 19% of the disclosed total.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.